|
CREB5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.674527266322E-13 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.79569692448922E-11 |
| Normal-vs-Stage2 |
1.328770E-01 |
| Normal-vs-Stage3 |
4.36420011240557E-10 |
| Normal-vs-Stage4 |
2.64219999990267E-07 |
| Stage1-vs-Stage2 |
1.067900E-02 |
| Stage1-vs-Stage3 |
4.495600E-01 |
| Stage1-vs-Stage4 |
4.196100E-02 |
| Stage2-vs-Stage3 |
4.017200E-03 |
| Stage2-vs-Stage4 |
1.479190E-03 |
| Stage3-vs-Stage4 |
2.118400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.00315328161105E-13 |
| Normal-vs-AfricanAmerican |
1.595650E-03 |
| Normal-vs-Asian |
1.00059999996738E-06 |
| Caucasian-vs-AfricanAmerican |
3.652400E-01 |
| Caucasian-vs-Asian |
2.784000E-01 |
| AfricanAmerican-vs-Asian |
7.888800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.6214000010435E-08 |
| Normal-vs-Female |
1.88948856560955E-12 |
| Male-vs-Female |
2.101800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.15592038350132E-12 |
| Normal-vs-Age(41-60Yrs) |
5.16029996511236E-10 |
| Normal-vs-Age(61-80Yrs) |
6.39669999999981E-05 |
| Normal-vs-Age(81-100Yrs) |
1.797010E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.465400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.782760E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.465000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.412600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.174800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.924200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.044340E-02 |
| Classical-VS-Follicular |
<1E-12 |
| Classical-VS-Other |
3.340400E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.11022302462516E-16 |
| Tall-VS-Other |
1.009410E-01 |
| Tall-VS-Normal |
1.62492241884138E-12 |
| Follicular-VS-Other |
2.022100E-02 |
| Follicular-VS-Normal |
2.802000E-01 |
| Other-VS-Normal |
2.001600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.428070E-04 |
| Normal-vs-N1 |
1.50320000003035E-07 |
| N0-vs-N1 |
3.168600E-04 |
|
|
